Background & Aims Treatment with immune checkpoint inhibitors (ICIs) for hepatocellular
carcinoma (HCC) prior to liver transplantation (LT) has been reported; however, ICIs may …

Simple Summary Hepatocellular carcinoma (HCC) represents one of the main indications
for liver transplantation. Over recent years, immune checkpoint inhibitor (ICI) therapy has …

Liver transplantation (LT) was originally described by Starzl as a promising strategy to treat
primary malignancies of the liver. Confronted with high recurrence rates, indications drifted …

Abstract In Asia–Pacific region, hepatocellular carcinoma is a serious health threat
attributing to over 600,000 deaths each year and account for over 70% of global cases …

Background Atezolizumab plus Bevacizumab combination therapy has recently emerged as
the new standard of care for unresectable HCC. Significant tumor burden reduction can be …

Simple Summary Transplant oncology is an evolving treatment ideal for patients suffering
from various cancers with poor prognoses. The concept essentially is the complete removal …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide, and its incidence has increased rapidly in the United States over the past two …

Simple Summary Cholangiocarcinoma is a relatively rare but deadly disease with
traditionally limited treatment options. The disease can be categorized by anatomic location …

Liver transplantation (LT) is a highly curative therapy for patients with hepatocellular
carcinoma (HCC). However, due to the shortage of donor livers and rapid progression of …

Simple Summary Hepatocellular carcinoma (HCC) is a common cause of cancer-related
deaths worldwide. During the early stages of the disease, HCC can be treated with surgery …